98%
921
2 minutes
20
Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492424 | PMC |
http://dx.doi.org/10.4046/trd.2012.73.4.231 | DOI Listing |
Fr J Urol
September 2025
Department of urology, Maison de Santé Protestante de Bordeaux-Bagatelle, Talence, France; Department of urology, HIA Robert-Picqué, Villenave d'Ornon, France.
Objectives: To evaluate the efficacy and safety of oral phosphodiesterase-5 inhibitors (PDE5Is) in the treatment of erectile dysfunction (ED). Additionally, to compare various PDE5Is and assess their suitability for different patient populations.
Evidence Acquisition: A systematic review of literature published from January 1999 to January 2023 was conducted following the PICOS criteria.
Andrology
August 2025
Division of Surgery and Interventional Science, University College London, London, UK.
Background And Objective: The Current European Association of Urology guidelines do not provide recommendation for combination of regenerative therapies with standard therapies for erectile dysfunction. The aim of this study was to compare the efficacy of combined regenerative therapy with monotherapy for erectile dysfunction.
Methods: A systematic review and meta-analysis were conducted following the 2020 Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines.
Am J Respir Crit Care Med
August 2025
Justus Liebig University, Internal Medicine, Giessen, Germany.
Background: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. The PVRI GoDeep meta-registry collects real-world data of PH patients from international PH referral centers.
Methods: ILD-PH patients and relevant subgroups (IIP, IPF) were stratified by pulmonary vascular resistance (PVR).
Niger Postgrad Med J
July 2025
Department of Surgery, Urology Unit, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria.
Background: Erectile dysfunction (ED) affects the physical and psychological health of a patient and his partner and can have a significant negative impact on their quality of life. Second-line therapies for ED include intracavernosal injections of vasoactive drug (ICIVAD) among others.
Aims: The aim of this study was to assess the efficacy of combination of papaverine and chlorpromazine (bimix) for the treatment of ED in patients who are unresponsive to 5-Phosphodiestrase inhibitors (PDE5-I).
Biomolecules
July 2025
Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410101, Israel.
Bariatric surgery involves major changes in the anatomy and physiology of the gastrointestinal tract, which may alter oral drug bioavailability and efficacy. Phosphodiesterase-5 inhibitor (PDE5i) drugs are the first-line treatment of erectile dysfunction, a condition associated with a higher BMI. In this paper, we examine the PDE5i vardenafil for possible post-bariatric changes in solubility/dissolution and absorption.
View Article and Find Full Text PDF